🔗 Share this article

While America proceeds with sweeping adjustments to its vaccination recommendations, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on Covid vaccines during the global health crisis and has zeroed in on possible fatalities after Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Vaccine Program

Health officials had intended to reveal sweeping changes to the childhood vaccination calendar in December, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of step with much of the global community with no evidence for improved outcomes. The planned update has been pushed back until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this year.

Consolidating Power at the Agency

This interim role may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon rolling back already-approved immunizations at the FDA.

The new acting director has often pushed for ending certain pediatric vaccine recommendations in the US in order to be more similar to Denmark, a country with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – traditionally the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

The appointee has no obvious background in medication creation, regulation or administrative roles, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Previous directors of CBER would “grasp legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who ran CBER have had.”

CDER has an enormous portfolio at the agency, the former commissioner stated.

“The public just zeroes in on the new drug program, but the off-patent medication office clears a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and every single one need to be managed,” Woodcock said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a major leadership component to the role, which manages over 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” the former official concluded.

Response and Contentious Programs

Regarding inquiries about Dr. Høeg's credentials and whether this assignment represents more teamwork among regulatory chiefs on vaccines, a spokesperson said that the “questions stem from flawed presumptions”.

“Her resume is consistent with the duties of her job,” the representative stated, citing the months Høeg spent guiding the agency head on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's recently launched priority voucher program, a controversial one-day drug-approval program that reportedly concerned her predecessors. “By what process are these medications being picked for this voucher program? Who takes the decisions?” Dr. Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards less stringent regulations of pharmaceuticals, except for shots.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if troubling, past, critics have noted. She published a study using non-validated crowd-sourced reports to estimate the incidence of heart inflammation after COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply Covid vaccines are more dangerous than they are.

Among her “desired changes” for the new federal leadership encompassed revising guidelines for new vaccines and discontinuing “unnecessary” immunizations, she said post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested barring young men from receiving COVID-19 vaccinations.

“She’s an all-around dogmatist who begins with her preconceived notions and works backwards to accommodate the science in a very disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other dissenters, {like|